Product Description
Busulfan is used treat a certain type of chronic myelogenous leukemia (CML; a type of cancer of the white blood cells). Busulfan is in a class of medications called alkylating agents. It works by slowing or stopping the growth of cancer cells in your body. (Sourced from: https://medlineplus.gov/druginfo/meds/a682248.html)
Mechanisms of Action: DNA Replication Inhibitor,RNA Transcription Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: CHU de Nantes
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Korea
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Extranodal NK-T-Cell Lymphoma|Lymphoma, Non-Hodgkin|Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RRTCLAlloSCT | P2 |
Recruiting |
Extranodal NK-T-Cell Lymphoma|Lymphoma, Non-Hodgkin |
2025-12-01 |
|
| BuMelMCRN001 | P2 |
Completed |
Multiple Myeloma |
2022-07-31 |